Dolca is a physician scientist, transplant nephrologist, and immunologist with over 20 years of experience across multiple therapeutic areas in academia, large pharmaceutical companies, and biotech. She is the CEO and co-founder of Neolaia Bio and currently serves as an independent board director of UCB and Ventus Therapeutics and as a scientific advisor for AnaptysBio.
Prior to Neolaia Bio, Dolca was a Venture Partner and Senior Advisor at Samsara BioCapital. Previously, she served as Executive Vice President, Head of R&D, and Chief Medical Officer at Equillium and as Chief Medical Officer at Principia Biopharma until its acquisition by Sanofi. In addition, Dolca held leadership roles across multiple large pharmaceutical companies. At Roche, she was Vice President and Global Head of Translational Medicine for Immunology, Inflammation, and Infectious Disease, contributing to the approval of Xofluza. At Pfizer, she was Vice President and Chief Development Officer of the Biosimilars R&D Unit, resulting in the approval of four biosimilar assets. She began her industry career at Bristol-Myers Squibb, involved in the registrational approval of belatacept.
Prior to her career in drug development, Dolca was a tenured track faculty member at Weill Cornell Medicine’s Department of Nephrology and Transplantation Medicine. She received a B.A. in sociology and an M.D. from Cornell University and Cornell Medical College.
